全文获取类型
收费全文 | 2925篇 |
免费 | 203篇 |
国内免费 | 2篇 |
学科分类
医药卫生 | 3130篇 |
出版年
2023年 | 27篇 |
2022年 | 30篇 |
2021年 | 134篇 |
2020年 | 106篇 |
2019年 | 123篇 |
2018年 | 151篇 |
2017年 | 91篇 |
2016年 | 103篇 |
2015年 | 120篇 |
2014年 | 178篇 |
2013年 | 189篇 |
2012年 | 262篇 |
2011年 | 232篇 |
2010年 | 122篇 |
2009年 | 107篇 |
2008年 | 187篇 |
2007年 | 181篇 |
2006年 | 146篇 |
2005年 | 154篇 |
2004年 | 112篇 |
2003年 | 95篇 |
2002年 | 66篇 |
2001年 | 43篇 |
2000年 | 34篇 |
1999年 | 27篇 |
1998年 | 14篇 |
1997年 | 11篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 2篇 |
1993年 | 5篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1973年 | 5篇 |
1972年 | 3篇 |
1971年 | 3篇 |
排序方式: 共有3130条查询结果,搜索用时 62 毫秒
1.
2.
3.
4.
5.
Aditya Kelkar Caroll Webers Rohit Shetty Jai Kelkar Nikhil Labhsetwar Abhishek Pandit Madhulika Malode Sayali Tidke 《Indian journal of ophthalmology》2020,68(10):2143
Purpose:To evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy.Methods:This was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients'' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days).Results:A total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was “non-affordability” (n = 120; 41.1%) followed by “no improvement in vision” (n = 83; 28.4%). “No improvement in vision” (42.2%) and “non-affordability” (37.5%) were higher among patients with DME. No association was found in gender- and treatment-wise distribution of reasons for loss to follow-up.Conclusion:The results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were “non-affordability” and “no improvement in vision.” 相似文献
6.
7.
8.
9.
10.